• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Electrocardiographic left atrial abnormalities and risk of incident stroke in hypertensive patients with electrocardiographic left ventricular hypertrophy
Conclusion: Abnormal PTFV1, a marker of left atrial abnormality, was strongly associated with incident stroke in hypertensive patients, independent of in-treatment SBP and other predictors of incident stroke. This association, in the absence of detectable atrial fibrillation, suggests that an underlying atrial cardiopathy may cause left atrial thrombus formation and a subsequent stroke without intervening clinically recognized atrial fibrillation.
Source: Journal of Hypertension - August 5, 2016 Category: Cardiology Tags: ORIGINAL PAPERS: Heart Source Type: research

Digoxin use and risk of mortality in hypertensive patients with atrial fibrillation
Conclusion: In hypertensive patients with ECG left ventricular hypertrophy with existing or new atrial fibrillation, digoxin use is not associated with a significantly increased risk of all-cause mortality after adjusting for other independent predictors of death and for the factors associated with the propensity to use digoxin in this population. These findings suggest that factors other than digoxin use may account for the increased mortality found with digoxin use in some studies. Clinical Trials Registration: http://clinicaltrials.gov/ct/show/NCT00338260?order=1
Source: Journal of Hypertension - June 5, 2015 Category: Cardiology Tags: ORIGINAL PAPERS: Therapeutic aspects Source Type: research

Blood pressure variability predicts cardiovascular events independently of traditional cardiovascular risk factors and target organ damage: a LIFE substudy
Background: Assessment of antihypertensive treatment is normally based on the mean value of a number of blood pressure (BP) measurements. However, it is uncertain whether high in-treatment visit-to-visit BP variability may be harmful in hypertensive patients with left ventricular hypertrophy (LVH). Methods: In 8505 patients randomized to losartan vs. atenolol-based treatment in the LIFE study, we tested whether BP variability assessed as SD and range for BP6–24months measured at 6, 12, 18 and 24 months of treatment was associated with target organ damage (TOD) defined by LVH on ECG and urine albumin/creatinine ratio at 2...
Source: Journal of Hypertension - November 12, 2015 Category: Cardiology Tags: ORIGINAL PAPERS: BP measurement Source Type: research

Nebivolol and incident cardiovascular events in hypertensive patients compared with nonvasodilatory beta blockers
Conclusion: The vasodilatory beta blocker nebivolol was associated with reduced incident cardiovascular events compared with nonvasodilatory beta blockers. Additional study of other beta blockers is necessary to determine if this is a vasodilatory beta blocker class effect or is specific to nebivolol. Graphical abstract: http://links.lww.com/HJH/B916
Source: Journal of Hypertension - May 1, 2022 Category: Cardiology Tags: ORIGINAL ARTICLES Source Type: research